Opinion on Company Issues in Switzerland

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

UBS: despite a return to profit, the Swiss bank's future still looks uncertain

UBS has revealed its first quarter of profit since Oswald Grubel took over as CEO 12 months ago. The Swiss banking group recorded a net profit of $1,130m, primarily driven by lower costs, lower own-credit charges and a one-off tax credit. However, this positive news disguises some serious concerns for the group.

Published By Datamonitor
17 Feb 2010
CommentWire
CommentWire

Panalpina: looking inward and upward

Despite weak international markets, Switzerland based Panalpina has produced impressive 2002 results. Taking a different strategy to some of its largest competitors, Panalpina has shown that a focus on internal efficiencies rather than strategic acquisitions can pay off, even in difficult economic conditions.

Published By Datamonitor
12 May 2003
CommentWire
CommentWire

Credit Suisse: plans to exit investment banking denied

Poor performance and corporate scandal has necessitated a review of Credit Suisse's investment banking and asset management business, CSFB. Credit Suisse has denied plans to spin-off the arm, but if CSFB is to justify a permanent reprieve, there will have to be a substantial turnaround in its performance.<BR />

Published By Datamonitor
22 Apr 2003
CommentWire
CommentWire

HSBC Republic: rich pickings in Switzerland

With increases in both client assets and profits, HSBC Republic Bank (Suisse) stands out from the deteriorating fortunes of many European wealth managers. While market conditions may slow progress, the continued focus on developing alternative investments and exploiting synergies with the HSBC group now looks set to expand the bank's footprint in the Swiss market.

Published By Datamonitor
14 Apr 2003
CommentWire
CommentWire

Pfizer: sale of a potential blockbuster

Pfizer's decision to keep Detrol and divest darifenacin to Novartis for $225 million is based purely on forecast projections. Detrol also has short-term blockbuster potential, while darifenacin may not offer significant advantages over Detrol or Johnson & Johnson's Ditropan, limiting its market penetration.

Published By Datamonitor
20 Mar 2003
CommentWire
CommentWire

Swiss Life: results worse than expected

Swiss Life, Switzerland's troubled leading insurer has revealed losses that exceeded even the gloomiest predictions. The insurer has been hit by the full force of the equity downturn, both on its asset levels and on a string of ambitious investments made at the height of the boom.<BR />

Published By Datamonitor
10 Mar 2003
CommentWire
CommentWire

Nestle: giant that keeps on growing

Last year, Nestle's steady-as-a-rock approach produced a strong set of full-year results. This year, as it unveils another set of impressive results, it seems its real strength is its consistency. With more of the same due for 2003, there will be no let up for those chasing the global leader.

Published By Datamonitor
28 Feb 2003
CommentWire
CommentWire

UBS: offshore private banking given an overhaul

UBS is uniting its five smallest private banks under a single holding company in reaction to poor fourth quarter results in its offshore business. This latest consolidation illustrates UBS' shift away from its traditional market in favor of European onshore banking.

Published By Datamonitor
19 Feb 2003
CommentWire
CommentWire

Roche: synergies provide boost despite vitamin deficiency

Roche's acquisition of Disetronic looks set to boost its presence in the diabetes market. But its enthusiasm will be tempered by news that the spin-off of its vitamin business will reap lower rewards than expected, while further funds must be set aside to settle price rigging claims. Even so, Roche and Disetronic will enjoy some valuable synergies.

Published By Datamonitor
12 Feb 2003
CommentWire
CommentWire

Hepatitis A vaccine: more protection than expected

A new study suggests the hepatitis A vaccine may provide immunity for over 20 years. A new Swiss study predicts that two doses of the hepatitis A vaccine will provide immunity for over 20 years. This is longer than previously thought.<BR />

Published By Datamonitor
13 Dec 2002

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.